Navigation Links
Personalizing revascularization strategy for STEMI patients is vital, EuroPCR panel finds
Date:5/21/2014

21 May 2014, Paris, France: A Great Debate at EuroPCR 2014 saw experts discussing the role of the two most valuable strategies to save the lives of ST-segment Elevation Myocardial Infarction (STEMI) patients: primary percutaneous coronary intervention (PCI) and thrombolysis.

Both these are effective treatments that actively save lives, and when there is no option for primary percutaneous coronary intervention, thrombolysis is the way to proceed, participants heard. The topic of the Great Debate, 'Primary PCI for STEMI: an emergency!' was selected ahead of the session by the interventional cardiology community, according to a vote on the EuroPCR website.

Thomas Cuisset, University Hospital, Marseille, France, noted that the goal of the session was to highlight the current clinical issues with the optimisation of primary PCI, and discuss the specifics of the technique, devices and adjunctive pharmacology.

"The spirit and core of the session was interaction between the facilitators and audience who sent in their questions throughout the session. Within this, we sought to highlight that primary PCI has to be a personalised intervention. Within the 'STEMI box', we are dealing with many very different patients and so the choice of drugs, vascular access and use (or not) of thromboaspiration, needs to be tailored to fit the patient," he said.

The final goal in STEMI is early revascularisation and in some geographies, for various reasons, primary PCI is delayed and therefore a pharmacoinvasive strategy can be a good alternative in such areas, the panel agreed.

Sajidah Khan, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa, emphasised that the efforts for treating STEMI comes from the recognition that the biggest impact on survival depends on establishing reperfusion within the first three hours of the onset of chest pain.

"The most powerful method of reducing mortality is to use whatever method you have at hand to treat the patient within three hours, because that is the window of greatest opportunity for treatment to impact on survival and outcomes," she said.

Khan noted that interventional cardiologists recognise that primary percutaneous coronary intervention was the best way to open the artery, ie. the gold standard. However, she pointed out that in resourced-limited environments where the availability of cath labs and interventional cardiologists could be a challenge, alternative strategies such as thrombolysis had a place in the treatment armamentarium.

"It is very reassuring for those of us who work in resource-scarce environments, that thrombolysis, if given correctly, is shown to be equivalent to PCI. However, we have to be cautious about the bleeding risk, particularly in the elderly. In those over 75, the benefit of primary PCI clearly outshines thrombolysis. In the developing world, we see that the age of the patient presenting with ST elevation is much younger and it is reassuring to know that the risk of bleeding from thrombolysis is lower in this population," she said.

Research shows that the bulk of mortality from coronary artery disease is shifting to middle and low income countries where access to cath labs may be limited, Khan said. She also pointed out that the need for research that compares the outcomes of thrombolysis with PCI, in countries that have widespread access to cath labs, has been interesting to see. "This points to the fact that merely having the access to the cath lab does not necessarily translate to every patient reaching the lab and undergoing revascularisation within three hours," she said.


'/>"/>

Contact: Isabelle Uzielli
iuzielli@europcr.com
EuroPCR
Source:Eurekalert

Related medicine news :

1. Personalizing biologic treatment to individual patients with rheuatoid arthritis is cost-effective
2. Personalizing medicine: New American Chemical Society Prized Science video
3. Personalizing prostate specific antigen testing may improve specificity, reduce biopsies
4. Personalizing prostate cancer screenings
5. Results released for first multicenter study of hybrid revascularization
6. New ESC-EACTS guidelines on myocardial revascularization to be released at EuroPCR 2014
7. White House Drug Policy Shifts Strategy
8. Discovery suggests new combination therapy strategy for basal-like breast cancers
9. Strategy discovered to activate genes that suppress tumors and inhibit cancer
10. New drug strategy attacks resistant leukemia and lymphoma
11. VisionWare and Serco Partner to Enable ‘Digital by Default’ Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Linda, CA (PRWEB) , ... May 24, 2016 ... ... fluorescent cell imaging; high content imaging; multiplex immunoassays are widely used for cell ... important for labs to maximize their quality and efficiency in these areas. , ...
(Date:5/23/2016)... ... 23, 2016 , ... On the occasion of his 25th Anniversary of changing ... loss process: , New patients have a consultation and evaluation (done by Dr. Ferdico ... , Body Composition Analysis, There are 15 things that each patient gets checked for, ...
(Date:5/23/2016)... ... 23, 2016 , ... According to an article published May 11th ... birth of her son, Rockwell Lloyd Liu, and notes that gestational surrogacy helped make ... Bill” star explains that, as a career oriented single woman, gestational surrogacy made parenthood ...
(Date:5/23/2016)... ... May 23, 2016 , ... NYDNRehab, a New York City-based ... athletes. This is the first time this type of technology, which was developed by ... to the public in New York. , With over 10 million sport injuries ...
(Date:5/23/2016)... ... May 23, 2016 , ... California State University Northridge ... quality of life and is currently focusing on ways to improve how people ... tested through research to find out whether watching them could have a significant ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... SAN FRANCISCO, Calif. , May 19, 2016 /PRNewswire/ ... a biopharmaceutical company developing novel therapeutics for the treatment ... announced that new GBT440 data will be presented in ... 21 st Congress in Copenhagen ... ongoing Phase 1/2 GBT440-001 study in sickle cell disease ...
(Date:5/19/2016)... 2016 BioLineRx Ltd. (NASDAQ/TASE: BLRX) ... treatment of multiple cancer and hematological indications, will be ... abstract titled " Clinical response in relapsed/refractory AML patients ... BL-8040, a potent CXCR4 antagonist; results of a Phase ... at the European Hematology Association 21st Congress, to be ...
(Date:5/19/2016)... CAMBRIDGE, Massachusetts , May 19, 2016 ... pharmaceuticals and diagnostics based on the gut microbiome, is pleased ... Cambridge, MA to support its operations ... office is located at Kendall Square, the heart of ... global hub for transforming scientific insights into new drugs. The ...
Breaking Medicine Technology: